



Universiteit
Leiden
The Netherlands

Early clinical and imaging features of rheumatoid arthritis: towards a more complete picture

Dijk, B.T. van

Citation

Dijk, B. T. van. (2024, September 24). *Early clinical and imaging features of rheumatoid arthritis: towards a more complete picture*. Retrieved from <https://hdl.handle.net/1887/4092968>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4092968>

Note: To cite this publication please use the final published version (if applicable).

Chapter 6

Intermetatarsal bursitis, a novel feature of juxta-articular inflammation in early rheumatoid arthritis related to clinical signs: results of a longitudinal magnetic resonance imaging study

Bastiaan T. van Dijk¹, Yousra J. Dakkak¹, Xanthe M.E. Matthijssen¹,
Ellis Niemantsverdriet¹, Monique Reijnierse², Annette H.M. van der Helm-van Mil^{1,3}

¹ Department of Rheumatology, Leiden University Medical Centre, Leiden, the Netherlands

² Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands

³ Department of Rheumatology, Erasmus Medical Centre, Rotterdam, the Netherlands

Arthritis Care Res (Hoboken). 2022 Oct;74(10):1713-1722.

ABSTRACT

Objective. Intermetatarsal bursae in the forefeet possess a synovial lining, similarly to joints and tendon sheaths. Inflammation of these bursae (intermetatarsal bursitis; IMB) was recently identified as specific for early RA. We hypothesised that if IMB is indeed an RA feature, then it associates with 1) other local inflammatory measures (synovitis, tenosynovitis and osteitis), 2) clinical signs and 3) responds to DMARD therapy similarly as other local inflammatory measures.

Methods. 157 consecutive early RA patients underwent unilateral contrast-enhanced 1.5 Tesla forefoot MRI at diagnosis. MRIs were evaluated for IMB presence, and for synovitis/tenosynovitis/osteitis in line with the RA MRI scoring-system (summed as RAMRIS inflammation). MRIs at 4/12/24 months were evaluated for IMB presence and size in patients who had IMB at baseline and received early DMARD therapy. Logistic regression and generalised estimating equations were used. Stratification for ACPA status was performed.

Results. 69% of RA patients had ≥ 1 IMB. In multivariable analysis on bursa-level, presence of IMB was independently associated with local presence of synovitis and tenosynovitis (OR 1.7 (95%CI 1.1–2.6) and 2.8 (1.8–4.4), respectively), but not osteitis. On patient level, IMB presence was most strongly associated with tenosynovitis (2.9 (1.6–5.2)). IMB presence associated with local joint swelling (2.7 (1.3–5.3)) and tenderness (1.7 (1.04–2.9)) independent of RAMRIS inflammation. During treatment, IMB size decreased between 0–12 months. This decrease associated with decrease in RAMRIS inflammation; which was driven by decreases in synovitis. Within ACPA-positive and ACPA-negative RA similar results were obtained.

Conclusion. IMB particularly accompanies inflammation of the synovial lining of joints and tendon sheaths, showed a similar treatment response after DMARD initiation and associates with typical clinical signs. These findings suggest that IMB represents a frequently present novel feature of juxta-articular synovial inflammation in RA.

SIGNIFICANCE AND INNOVATIONS

- Inflammation of the synovium-lined intermetatarsal bursae (intermetatarsal bursitis; IMB) is frequently present at diagnosis of RA (69%), both in ACPA-positive (75%) and ACPA-negative (64%) patients, and associates with local joint tenderness and swelling.
- IMB also associates with known RA-related MRI-detected inflammation (synovitis and tenosynovitis).
- After initiation of disease modifying anti-rheumatic drugs (DMARDs), IMB decreases in a fashion similar to known RA-related MRI-detected inflammation and disease activity (DAS44), suggesting a treatment response.
- These findings imply that IMB is indeed a novel juxta-articular inflammatory feature of RA.

INTRODUCTION

Rheumatoid arthritis (RA)-related local inflammation in the hands and forefeet can be reliably and sensitively assessed using magnetic resonance imaging (MRI),[1,2] which is recommended by the European League against Rheumatism (EULAR) for early detection of RA.[3] Three features of local inflammation are assessed according to the conventionally used RA MRI scoring system (RAMRIS): synovitis, tenosynovitis and osteitis.[4] Although RA is traditionally known for targeting the synovial lining of (small) joints (i.e. synovitis), MRI-studies have shown that juxta-articular synovial inflammation in the form of tenosynovitis is typical for the disease as well: tenosynovitis at the small joints represents inflammation of the synovial lining of tendon sheaths, is specific for early RA and contributes to typical RA-related symptoms.[5-8]

Forefoot involvement is frequent in RA and an important cause of symptoms and disability.[9] Specifically in the forefeet, in addition to synovial joints and tendon sheaths, another distinct tissue with a synovial lining but without connection to the metatarsophalangeal (MTP) joints is present and may become inflamed: the intermetatarsal bursae.[10-13] MRI-detected intermetatarsal bursitis (IMB) was recently identified as highly specific for early RA and to be less frequent in healthy controls and arthritides other than RA.[14] Although IMB has been described in established RA and is associated with foot-related disability,[15,16] its role in early disease has barely been explored. Two studies have thus far reported a prevalence of IMB in early RA of 63% and 69%.[14,17] One of these studies also reported that IMB associates with RA independently from several clinical factors (age, gender and BMI).[14]

Bursae have a function in reducing mechanical strain and friction. Mechanical strain (e.g. due to deformities or altered mechanical loading) is suggested to be involved in bursitis development, but reports on its role in development of IMB in early RA are contradictory.[18-20] Shortly, there is some evidence suggesting that IMB is a feature of early RA, but scientific data are scarce.

Because RA is the most common inflammatory disease in the field of rheumatology and foot complaints are common in people with RA, we believe it is essential to understand the pathophysiology of forefoot complaints. The forefeet undergo mechanical loading during walking. In RA of recent onset, mechanical loading may possibly influence forefeet inflammation and/or aggravate forefeet symptoms. As such, IMB can be part of inflammation that relates to symptoms. We hypothesised that if IMB is indeed a feature of early RA, it should associate with known MRI inflammation measured by the RAMRIS (synovitis, tenosynovitis and osteitis), as well as with typical signs related to RA (joint tenderness and swelling) at diagnosis. To determine this we performed a large cross-sectional MRI study. Finally, we hypothesised that IMB should also respond to treatment with disease-modifying antirheumatic drugs (DMARDs), analogous to MRI inflammation measured by the RAMRIS.[21,22] Follow-up MRIs were evaluated to study this.

PATIENTS AND METHODS

Patients

The Leiden Early Arthritis Clinic (EAC) is an inception cohort based in the Leiden University Medical Centre (LUMC) in the Netherlands enrolling patients with clinically apparent arthritis of recent onset (symptom duration <2 years) since 1993. Its design has been described previously.[23] At baseline, tender and swollen joint counts were conducted, DAS44 was assessed and blood samples were taken to measure C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), IgG anti-citrullinated protein antibodies (ACPA) and IgM rheumatoid factor (RF).[24] Follow-up visits were scheduled at 4 months, 12 months and yearly thereafter. All patients provided written informed consent.

From June 2013 onwards the EAC protocol included contrast-enhanced MRI of the forefoot. For the current study, we included 157 consecutive DMARD naïve early RA patients from the EAC who were enrolled from June 2013 to March 2016. 14 early RA patients were excluded because of missing baseline MRI and 5 because of insufficient quality of the MR images. RA was defined as a clinical diagnosis plus fulfilment of the 2010 RA criteria within one year after inclusion.[25]

Clinical signs typical for RA

Joint tenderness and swelling were assessed at physical examination by a trained research nurse. Joint swelling was also assessed independently by a rheumatologist and was considered positive if both assessors agreed on its presence in the same joint.[26] Research nurses participate regularly in consensus exercises for joint examination led by a rheumatologist to maintain interobserver agreement.

MRI scanning and baseline evaluation

Shortly after the first visit (when clinical assessments were done) and before any DMARDs were started (the period between first visit and MRI was 9 days on average), all patients underwent unilateral contrast-enhanced 1.5T MRI (ONI, GE, Wisconsin, USA) of the MTP joints (1 to 5) on the most painful side. In the case of symmetrically severe symptoms the dominant side was scanned. The MRI protocol is described in more detail in Online Supplementary Data 1. All MRIs were scored blinded for clinical data.

The intermetatarsal bursae lie in the superior intermetatarsal spaces, which are bordered medially and laterally by the metatarsal heads, dorsally by the deep dorsal aponeurosis and plantarly by the deep transverse metatarsal ligament.[10,12] IMB was therefore defined as contrast-enhancement of the bursa in the superior intermetatarsal space, with or without rim enhancement, visible on ≥ 2 consecutive slices in both planes (axial and coronal). For each superior intermetatarsal space (4 per foot) presence of IMB was recorded by two independent readers, who then determined the final scores by consensus: an IMB lesion was considered present if both agreed on this. This IMB scoring method was described previously; the specificity for RA of IMB presence assessed in this manner was 84% compared to healthy controls.[14] Next to IMB presence, also the size of the lesions in dorsoplantar direction (in millimetres (mm)) was recorded,[14] to enable assessment of changes in size at follow-up. Size measurements are described in more detail in Online Supplementary Data SD2.

To assess the relation between IMB and other MRI measures of local inflammation, MRIs were also evaluated for synovitis, tenosynovitis and osteitis in line with the RAMRIS by two independent readers as described previously.[2,27,28] To obtain the total RAMRIS inflammation score, for each patient the scores for synovitis, tenosynovitis and osteitis were summed; the average of the scores of both readers was used.[29] At joint level, presence of RAMRIS inflammation was stringently defined based on consensus: synovitis, tenosynovitis or osteitis were considered present per location if that feature was scored as ≥ 1 by both readers independently, concordant to the literature.[26] Detailed information on RAMRIS inflammation scoring is presented in Online Supplementary Data 1.

Follow-up MRIs

MRIs were repeated over time (scheduled at 4, 12 and 24 months from baseline) in patients included from June 2013 until February 2015; a flowchart illustrating patient selection for longitudinal analyses is presented in Online Supplementary Figure SF1. The course of IMB was evaluated longitudinally in patients who had ≥ 1 IMB lesion at baseline and received early DMARD therapy. ‘Early’ was defined as DMARD initiation (including glucocorticoids) within 100 days from first presentation at the outpatient clinic.

For IMB both its presence and lesion size were evaluated. For the latter, a composite measure was used: the averaged IMB size (in mm), calculated by summing the dorsoplantar sizes of all IMB lesions in any intermetatarsal space and dividing the result by four (the maximum number of IMB lesions). The dorsoplantar size was used and not the transversal size, because intermetatarsal bursae are confined transversally by the metatarsal heads and may, theoretically, distend dorsoplantarly more freely.[30]

MRIs were scored in known time order. IMB presence and -size were assessed without simultaneously performing RAMRIS scoring. In addition, the same set of MRIs was scored by another independent trained reader, who performed RAMRIS scoring. Interreader and intrareader intraclass correlation coefficients (ICCs) were 0.90 and 0.85, respectively (Online Supplementary Table ST1). For the RAMRIS, inter- and intrareader ICCs were ≥ 0.90 (as published previously[31]).

Statistical analyses

Firstly, the association between presence of IMB and RAMRIS inflammation at baseline was assessed at patient and bursa level. At patient level, univariable logistic regression was used with continuous scores for RAMRIS inflammation (synovitis, tenosynovitis, osteitis and total RAMRIS inflammation score) as independent variables. Bursa level analyses were performed using univariable generalised estimating equations (GEEs) with presence of RAMRIS inflammation (synovitis, tenosynovitis, osteitis and presence of any of these three) in the two joints neighbouring the bursa as independent variables. Both at patient and bursa level, multivariable models with synovitis, tenosynovitis and osteitis as separate independent variables were performed, since these features often co-occur.

Secondly, it was assessed at joint level whether presence of IMB at baseline contributes to two clinical signs typical for RA: joint tenderness and swelling. Univariable GEEs were used with tenderness or swelling of the MTP joint as outcome and IMB presence in the adjacent intermetatarsal space as independent variable. Multivariable GEEs adjusted for concurrent presence of RAMRIS inflammation (synovitis, tenosynovitis

or osteitis). The first MTP joint was not included in these analyses because it is a predilection site for other diseases than RA (e.g. gout and osteoarthritis) which could introduce tenderness or swelling unrelated to RA.[26]

Longitudinally, at patient level, mean averaged IMB size and total RAMRIS inflammation were modelled over time using GEEs and visualised in one graph. The disease activity score (DAS44; calculated with a four component formula)[32] was plotted as well. Associations between the time-courses of IMB and RAMRIS inflammation were assessed at patient level using univariable GEEs with changes in averaged IMB size as dependent and changes in RAMRIS inflammation (synovitis, tenosynovitis, osteitis and total scores) as independent variables. Again, also a multivariable GEE with the three inflammation features as separate independent variables was performed. GEE-models were limited to the 0–4 and 4–12 months intervals to optimise the fit, since thereafter patient numbers were lower and MRI-detected inflammation was stable.

Sensitivity analyses were performed by repeating the patient level longitudinal analyses in the subgroup of patients who received methotrexate as initial DMARD therapy since methotrexate was most often used as first line DMARD therapy, as recommended by international guidelines for RA-management.[33]

Analyses were repeated with stratification for ACPA-status, since ACPA-positive and ACPA-negative RA are considered different entities.[22,34,35] Effects of ACPA status on the time-courses of IMB and total RAMRIS inflammation at patient level were assessed by adding ACPA status and the interaction between ACPA status and MRI timepoint as independent variables to the longitudinal models.

IBM SPSS (version 25) was used. Two-sided p-values <0.05 were considered statistically significant.

RESULTS

Patients

Baseline characteristics are presented in Table 1. IMB was present in 109 patients (69%). IMB was more often present in patients with a higher swollen joint count, and tended to be more often present in ACPA-positive RA (75% versus 64% in ACPA-negative RA, p=0.13).

Table 1. Baseline characteristics of all RA patients studied; and according to presence of IMB

	IMB at baseline		
	All patients (n = 157)	Present (n = 109)	Absent (n = 48)
Age in years, mean \pm SD	59 \pm 14	58 \pm 14	61 \pm 14
Female, n (%)	109 (69)	74 (68)	35 (73)
BMI, mean \pm SD	26 \pm 5	26 \pm 4	26 \pm 5
Symptom duration in weeks, median (IQR)	11 (5–28)	10 (5–27)	12 (5–31)
SJC, median (IQR)*	7 (3–11)	8 (4–11)	4 (1–11)
TJC, median (IQR)	5 (3–7)	5 (3–7)	5 (3–8)
Swollen MTP joint(s), n (%)	57 (36)	43 (39)	14 (29)
ESR (mm/hour), median (IQR)	28 (14–45)	28 (14–41)	27 (10–49)
DAS44, mean \pm SD	3.1 \pm 0.8	3.1 \pm 0.8	3.0 \pm 0.8
ACPA-positive, n (%)	83 (53)	62 (57)	21 (44)
RF-positive, n (%)*	101 (64)	76 (70)	25 (52)
Number of IMB lesions, median (IQR)	1 (0–3)	2 (1–3)	–

* Statistically significant at the 0.05 level

Abbreviations: ACPA = anti-citrullinated protein antibodies; DAS = disease activity score; ESR = erythrocyte sedimentation rate; IMB = intermetatarsal bursitis; IQR = interquartile range; RF = rheumatoid factor; SD = standard deviation; SJC = swollen joint count; TJC = tender joint count

IMB occurs together with tenosynovitis and synovitis

Patients with MRI-detected IMB were more likely to have higher total RAMRIS inflammation scores (Table 2). Also evaluation of synovitis, tenosynovitis and osteitis separately showed that patients with IMB were more likely to have higher scores for all these inflammatory features. Multivariable analyses showed that IMB presence was associated with high tenosynovitis scores. Thus, patients with a higher severity of tenosynovitis had IMB more frequently.

Then analyses were done at bursa-level. IMB was more often present at locations with synovitis, tenosynovitis or osteitis in the adjacent MTP joints (Table 3). In multivariable analyses, the presence of IMB was associated with local presence of synovitis and tenosynovitis (OR 1.69 (95%CI 1.12–2.57) and 2.83 (1.80–4.44), respectively). In contrast, it was not associated with presence of inflammation in the adjacent bones (osteitis) in multivariable analysis.

Table 2. The association between the presence of IMB and RAMRIS inflammation scores in the forefoot at patient level at first presentation (n = 157)

	Univariable				Multivariable [*]	
	Range	Median (IQR)	OR (95% CI)	p	OR (95% CI)	p
Total RAMRIS inflammation	0–30	4 (1–9)	1.51 (1.28–1.78)	<0.001	–	
Synovitis	0–10	1 (0–3)	1.98 (1.45–2.72)	<0.001	1.12 (0.77–1.65)	0.55
Tenosynovitis	0–12	1 (0–3)	3.42 (1.97–5.95)	<0.001	2.92 (1.62–5.24)	<0.001
Osteitis	0–20	1 (0–3)	1.70 (1.27–2.27)	<0.001	1.38 (0.97–1.97)	0.074

* Including synovitis, tenosynovitis and osteitis scores as independent variables

Abbreviations: CI = confidence interval; IMB = intermetatarsal bursitis; IQR = interquartile range; OR = odds ratio; RAMRIS = Rheumatoid Arthritis MRI Inflammation Scoring System

Table 3. The association between the presence of IMB and presence of RAMRIS inflammation in neighbouring joints at first presentation (n = 628 bursae)

	Univariable		Multivariable [*]	
	OR (95% CI)	p	OR (95% CI)	p
Any feature	2.67 (1.91–3.73)	<0.001	–	
Synovitis	2.63 (1.84–3.76)	<0.001	1.69 (1.12–2.57)	0.013
Tenosynovitis	3.69 (2.40–5.67)	<0.001	2.83 (1.80–4.44)	<0.001
Osteitis	1.99 (1.33–2.98)	0.001	1.30 (0.81–2.08)	0.28

* Including synovitis, tenosynovitis and osteitis presence as independent variables


Abbreviations: CI = confidence interval; IMB = intermetatarsal bursitis; IQR = interquartile range; OR = odds ratio; RAMRIS = Rheumatoid Arthritis MRI Inflammation Scoring System

Two example MR images of IMB co-occurring with tenosynovitis are presented in Figure 1. Additional example MR images are presented in the Online Supplementary file (Online Supplementary Figure SF2).

IMB contributes to joint tenderness and swelling independent of RAMRIS inflammation

157 RA patients contributed 628 MTP joints, of which 200 (32%) were tender and 81 (13%) were swollen. Joints with adjacent IMB were more likely to be tender (OR 2.1 (1.3–3.4)) and swollen (OR 3.1 (1.6–6.2)). Multivariable analyses showed that IMB presence associated with both clinical signs independent of synovitis, tenosynovitis and osteitis (adjusted OR 1.7 (1.04–2.9) for tenderness and 2.7 (1.3–5.3) for swelling).

Figure 1. MR images of two DMARD-naive early RA patients showing MRI-detected IMB co-occurring with (A) synovitis and flexor tenosynovitis and with (B) extensor tenosynovitis



Coronal T1-weighted fat suppressed images after gadolinium administration of the forefoot at the level of the metatarsal heads.


Both patients: Enhancement of thickened synovium in the intermetatarsal spaces 1–3, consistent with IMB (arrows).

Patient A (female, 33 years old): Peripheral enhancement in the 3rd intermetatarsal space with a central area of lower signal intensity, consistent with fluid. At the 3rd MTP joint, there is enhancement surrounding the flexor tendon consistent with tenosynovitis[47] (dotted arrows), as well as synovitis (arrowhead).

Patient B (female, 41 years old): Peripheral enhancement in the 1st intermetatarsal space with a central area of lower signal intensity consistent with fluid. In addition, there is enhancement surrounding extensor tendons, consistent with tenosynovitis (dotted arrows).[47]

Abbreviations: DMARD = disease-modifying antirheumatic drug; IMB = intermetatarsal bursitis; MR = magnetic resonance; MRI = magnetic resonance imaging; MTP = metatarsophalangeal

Figure 2. IMB size and total RAMRIS inflammation in the forefoot over time (n = 55): (A) in all patients and (B) in ACPA-positive and ACPA-negative patients separately



* β signifies the association of change in averaged IMB size with change in total RAMRIS inflammation between 0–12 months, estimated using GEEs. IMB-decrease was statistically significantly associated with total RAMRIS inflammation decrease at the 0.05 level in all patients (A) and in both ACPA-subsets (B). Abbreviations: ACPA = anti-citrullinated protein antibodies; CI = confidence interval; GEE = generalised estimating equation; IMB = intermetatarsal bursitis; mm = millimetres; RAMRIS = Rheumatoid Arthritis MRI Inflammation Scoring System

IMB decreases after DMARD initiation in a fashion similar to synovitis and tenosynovitis

Out of the 109 patients who were IMB positive at baseline, 101 received early DMARD therapy of which 73 patients were included before February 2015 (the period wherein follow-up MRIs were made; Online Supplementary Figure SF1). Follow-up MRI was available for 55 (75%) of these patients. Longitudinal MRIs (at 4/12/24 months) of these 55 patients were evaluated to assess the time course of IMB after DMARD-initiation.

The time-courses of IMB and total RAMRIS inflammation are depicted in Figure 2A. Both measures decreased statistically significantly between baseline and 12 months: mean averaged IMB size was 6.7 mm at baseline and decreased with 3.1 mm (95%CI 2.2–4.1, $p < 0.001$), while mean total RAMRIS inflammation was 7.7 points at baseline and decreased with 4.1 points (2.4–5.7, $p < 0.001$) between 0 and 12 months.

Next, we assessed the relation between changes in IMB and simultaneous changes in RAMRIS inflammation over time. Between baseline and 12 months, greater decreases in averaged IMB size statistically significantly associated with greater decrease in total RAMRIS inflammation (Figure 2A). The three RAMRIS inflammation features were also assessed separately for their relation with IMB decrease (Online Supplementary Table ST3). In univariable analyses, patients with greater decreases in synovitis and tenosynovitis on average underwent a greater simultaneous decrease in IMB. Multivariably, IMB decrease was associated with synovitis decrease in the same time interval. Notably, IMB decrease was not related to osteitis decrease, both in univariable and multivariable models. Lastly, DAS44 over time in relation to IMB was plotted (Online Supplementary Figure SF3).





Longitudinal MRI-images of a patient showing decreasing IMB are presented in Figure 3. An additional series is presented in the Online Supplementary file (Online Supplementary Figure SF4).

> Figure 3. Longitudinal MR images of decreasing IMB in an RA patient

Coronal T1-weighted fat suppressed images after gadolinium administration of the forefoot at the level of the metatarsal heads of an early RA patient (female, 33 years old at baseline; corresponds to figure 1A). The different time-points are shown vertically.

Arrows point to IMB. IMB is visible in intermetatarsal spaces 1–3 with concomitant synovitis and flexor tenosynovitis at the 3rd MTP joint. All inflammation decreases after DMARD initiation; minimal IMB in the 3rd space remains visible after two years.

Abbreviations: IMB = intermetatarsal bursitis; MR = magnetic resonance; MTP = metatarsophalangeal; RA = rheumatoid arthritis



Sensitivity analysis

47 of 55 longitudinally studied patients (85%) received methotrexate as initial DMARD therapy. Longitudinal analyses were repeated in this subgroup. Results were similar to those of the main analyses (Online Supplementary Tables ST7 & ST8; Online Supplementary Figures SF5 & SF6).

Analyses stratified for ACPA-positivity

Analyses of the relation between IMB and RAMRIS inflammation at baseline and in the first year of follow-up did not show meaningful differences between ACPA-positive and ACPA-negative RA (Online Supplementary Tables ST4–ST6), except that in univariable analyses at baseline the association between IMB and osteitis was statistically significant only in ACPA-positive patients. IMB presence at baseline associated with local joint tenderness independent of RAMRIS inflammation only in ACPA-positive patients (adjusted OR 3.0 (1.6–5.6); Online Supplementary Table ST2). The association with joint swelling seemed present in both groups, but only reached statistical significance in ACPA-positive patients (adjusted OR 3.3 (1.2–9.1)).

Longitudinally, decreases in both averaged IMB size and total RAMRIS inflammation between 0 and 12 months appeared to be more pronounced in ACPA-negative RA (Figure 2B). This was statistically significant for IMB (2.4 mm (95%CI 0.4–4.4) greater decrease in ACPA-negative versus ACPA-positive RA), but not for total RAMRIS inflammation (0.2 (-3.1–3.6) points greater decrease in ACPA-negative versus ACPA-positive RA). Baseline values of averaged IMB size and total RAMRIS inflammation were not statistically significantly different.

DISCUSSION

RA is traditionally known as an auto-immune disease targeting the synovial lining of (small) joints. There is mounting evidence indicating that juxta-articular synovial inflammation is an important trait of the disease as well. Recently, tenosynovitis was the first feature of such juxta-articular inflammation to be identified as a trait of RA.[6] Our study shows that also IMB frequently occurs in RA at the time of diagnosis, especially when synovitis and tenosynovitis were also present, and that it contributes to joint tenderness and swelling independent of known MRI features. These data enhance our understanding of forefoot inflammation in RA and support the notion that IMB might be another feature of juxta-articular synovial inflammation in RA.

The current study is the first to investigate IMB in early RA during follow-up, and in relation to known RA inflammation features (RAMRIS inflammation). We demonstrated that IMB decreased after DMARD initiation; a decrease that was most strongly related to a decrease in synovitis severity. This decrease of IMB was as one would expect from an RA treatment response. These findings may therefore further support the notion that IMB is truly a feature of RA.

Recognition of IMB is clinically relevant since it could add to the set of RA features and characteristics that physicians may consider when evaluating patients with (suspected) RA. Our findings suggest that IMB contributes to the clinical appearance of metatarsalgia and arthritis. More specifically, it could aid in the interpretation of forefoot symptoms and walking disabilities in the absence of synovitis on imaging.

While IMB in RA has been described in small case reports and larger studies in long-standing disease,[16,36-38] the current study is the first large MRI study in early RA. The prevalence of MRI-detected IMB in our baseline sample was published previously and amounted to 69%,[14] which is in line with the 63% previously reported in a small MRI study in early RA (n=30 patients).[17] The results of the present and previous imaging studies are concordant in their finding that IMB is prevalent in a majority of RA patients at diagnosis. In addition, data of our study suggest that IMB is especially present in patients presenting with extensive inflammation, measured by the swollen joint count or total RAMRIS inflammation.

The association between IMB and joint swelling was described previously in early arthritis, which also included the RA patients studied here.[26] However, the current finding that this association is present in RA patients specifically, independent from RAMRIS inflammation, is novel. Moreover, we now also show that IMB contributes to joint tenderness, which is a subject of utmost importance from patient perspective.[39] The association of IMB with joint swelling appeared somewhat stronger than its association with tenderness, generating the question whether the latter is partly caused by the first. When restricting analyses to non-swollen joints only (n=540), the effect size changed only slightly (the OR adjusted for RAMRIS inflammation went from 1.7 (1.04-2.9) to 1.5 (0.8-2.8)). In our view, this suggests that IMB contributes not only to joint swelling but also to tenderness without clinical swelling.

IMB was frequently present in both ACPA-positive and ACPA-negative RA at diagnosis. The prevalence was higher in the ACPA-positive group, but this was not statistically significant. The association of IMB presence with simultaneous presence of synovitis (at joint level) and tenosynovitis (at patient and joint level) was also

positive in both groups. While ACPA-positive patients were more likely to have IMB in the presence of osteitis in univariable analyses, this association was not statistically significant in ACPA-negative patients. This difference between ACPA-positive and ACPA-negative RA is in line with previous findings showing that osteitis associates particularly with ACPA-positive RA.[40,41] Despite similar associations of IMB with RAMRIS inflammation, associations with joint tenderness and swelling were more prominent in ACPA-positive than ACPA-negative RA. In both RA groups however, IMB decreased significantly over time in a fashion similar to total RAMRIS inflammation. Moreover, patients in both groups showed greater IMB decrease when also total RAMRIS inflammation decreased more strongly. Thus, although ACPA-positive and ACPA-negative RA have differences in risk factors, presumed aetiology and severity of the disease course,[34,35,42] IMB is prevalent and behaves similarly in relation to RAMRIS inflammation in both disease subsets.

Hypothetically, mechanical strain could promote development of bursitis. If so, one may assume that IMB-decrease is secondary to decreasing mechanical pressure from reduction in neighbouring synovitis.[18-20] Exploratory analyses showed that IMB lesions with adjacent synovitis at baseline did not dissipate more often (44% after 12 months, vs. 57% for IMB-lesions without adjacent synovitis; $p=0.17$), arguing against a secondary treatment effect by decreasing mechanical pressure from neighboring synovitis.

We measured IMB size in dorsoplantar direction according to the literature and because this was expected to more accurately represent total lesion size than axial measurements. Intermetatarsal bursae are confined axially by the metatarsal heads and may therefore distend dorsoplantarly more freely.[30] Influence of mechanical factors on dorsoplantar distension was most likely limited, as MRIs were made in supine, non-weight bearing position. Still, potentially relevant aspects of the time course of IMB might have gone unnoticed by focusing on the dorsoplantar dimension. Ideally, total IMB volume is used, but reliable measuring methods were not available and beyond the scope of the current investigation.

An important strength of the current study was the relatively large sample size at baseline compared to previous imaging studies of IMB in early RA.[17,36] Secondly, results were robust across patient and joint level analyses. Lastly, owing to the design of the Leiden EAC which is an inception cohort with extensive follow-up including MRI scans at multiple timepoints, we were able to perform novel longitudinal analyses of MRI-detected IMB in early RA.

There are also limitations. Firstly, the method we used to score the presence and size of IMB lesions is novel and not yet systematically validated. On the other hand, it was developed in collaboration with an MSK radiologist with >20 years of experience and inter- and intra-reader reliability were good (ICCs ≥ 0.85). Secondly, MRIs were scored in chronological order to achieve better sensitivity to change, which is in line with the literature.[2,27,43-45] Theoretically, this may have caused bias in the form of greater change scores than would have been the case with blinding for time-order. However, impact on the main objective to assess associations between IMB and RAMRIS inflammation over time is assumed to be limited, as we have no reason to believe that the improvement in sensitivity to change is differential between IMB and RAMRIS inflammation. Thirdly, regression to the mean could have occurred in the longitudinal part of the study since only patients who were IMB-positive at baseline were included. It might be interesting to assess in a subsequent study whether IMB-negative patients may develop IMB over time despite receiving DMARDs or during flares. Furthermore, as RA patients were treated and we did not perform a randomized clinical trial with a placebo arm, we interpreted the decrease in DAS, RAMRIS inflammation and IMB as treatment response, but this was not formally proven. Although both IMB and RAMRIS inflammation decreased statistically and numerically significantly (by 46 and 53%, respectively), minimal reference values for determining a response in these measures are not available. We also had insufficient power to stratify analyses by individual DMARDs other than methotrexate. Finally, any association of IMB with deviations of forefoot bones (e.g. hallux valgus and hammer toes) which might hypothetically influence IMB could not be taken into account as no weightbearing radiographs were made.[18-20,46]

Recognition of IMB as an RA feature paves the way for further studying of its properties in the disease. A case report suggested that IMB can be recognised by the feature 'opening toes' related to enlargement of the space between adjacent toes.[38] Although such a clinical sign to detect IMB has the advantage of being less costly and time consuming than MRI, it has so far not been systematically studied. The contribution of IMB to walking disabilities, including the role of biomechanical factors such as pressure distribution, is another subject for further research. For RA patients with prominent foot symptoms and/or walking disabilities, it would be especially valuable to see if amelioration of IMB correlates with symptomatic and functional improvement and, if so, which individual DMARDs or additional therapeutic approaches influence IMB and forefoot symptoms. In addition it could be studied whether IMB is of pathophysiological relevance or just reflects extensive synovial inflammation pertaining to higher disease-activity. For example, the causal relation between synovitis, tenosynovitis and IMB could be investigated in a histopathological study differentiating the types of synovitis.

Lastly, although IMB has been reported to be detectable by ultrasound,[15] which is more easily accessible in daily practice than MRI, its correlation with MRI-detected IMB in early RA has not yet been studied.

In conclusion, IMB behaves in line with known RA characteristics: it particularly accompanies inflammation of the synovial lining of joints and tendon sheaths, showed a similar treatment response after DMARD initiation and contributes to typical clinical signs. These findings support the notion that IMB is a novel inflammatory feature of early RA.

REFERENCES

1. Østergaard M, Bird P, Gandjbakhch F, et al. The OMERACT MRI in Arthritis Working Group - Update on Status and Future Research Priorities. *J Rheumatol.* 2015;42(12):2470-2.
2. Dakkak YJ, Matthijssen XME, van der Heijde D, et al. Reliability of Magnetic Resonance Imaging (MRI) Scoring of the Metatarsophalangeal Joints of the Foot according to the Rheumatoid Arthritis MRI Score. *J Rheumatol.* 2019;jrheum.190258.
3. Colebatch AN, Edwards CJ, Østergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. *Ann Rheum Dis.* 2013;72(6):804-14.
4. Østergaard M, Peterfy CG, Bird P, et al. The OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging (MRI) Scoring System: Updated Recommendations by the OMERACT MRI in Arthritis Working Group. *J Rheumatol.* 2017;44(11):1706-12.
5. Nieuwenhuis WP, van Steenberghe HW, Mangnus L, et al. Evaluation of the diagnostic accuracy of hand and foot MRI for early Rheumatoid Arthritis. *Rheumatology.* 2017;56(8):1367-77.
6. Rogier C, Hayer S, van der Helm-van Mil A. Not only synovitis but also tenosynovitis needs to be considered: why it is time to update textbook images of rheumatoid arthritis. *Ann Rheum Dis.* 2020;79(4):546.
7. Mankia K, Agostino M-A, Rowbotham E, et al. MRI inflammation of the hand interosseous tendons occurs in anti-CCP-positive at-risk individuals and may precede the development of clinical synovitis. *Ann Rheum Dis.* 2019;78(6):781.
8. Eshed I, Feist E, Althoff CE, et al. Tenosynovitis of the flexor tendons of the hand detected by MRI: an early indicator of rheumatoid arthritis. *Rheumatology.* 2009;48(8):887-91.
9. Brooks F, Hariharan K. The rheumatoid forefoot. *Curr Rev Musculoskelet Med.* 2013;6(4):320-7.
10. Theumann NH, Pfirrmann CW, Chung CB, et al. Intermetatarsal spaces: analysis with MR bursography, anatomic correlation, and histopathology in cadavers. *Radiology.* 2001;221(2):478-84.
11. Awerbuch MS, Shephard E, Vernon-Roberts B. Morton's metatarsalgia due to intermetatarsophalangeal bursitis as an early manifestation of rheumatoid arthritis. *Clin Orthop Relat Res.* 1982(167):214-21.
12. Chauveaux D, Le Huec JC, Midy D. The supra-transverse intermetatarsocapital bursa: a description and its relation to painful syndromes of the forefoot. *Surg Radiol Anat.* 1987;9(1):13-8.
13. Jovanovic MS, Royer J, Roy PE, et al. A comparative study of the spaces between the metacarpal and metatarsal heads. *Surg Radiol Anat.* 1990;12(1):31-6.
14. Dakkak YJ, Niemantsverdriet E, van der Helm-van Mil AHM, Reijnen M. Increased frequency of intermetatarsal and submetatarsal bursitis in early rheumatoid arthritis: a large case-controlled MRI study. *Arthritis Res Ther.* 2020;22(1):277.
15. Bowen CJ, Culliford D, Dewbury K, et al. The clinical importance of ultrasound detectable forefoot bursae in rheumatoid arthritis. *Rheumatology.* 2009;49(1):191-2.
16. Hammer HB, Kvien TK, Terslev L. Intermetatarsal bursitis is frequent in patients with established rheumatoid arthritis and is associated with anti-cyclic citrullinated peptide and rheumatoid factor. *RMD open.* 2019;5(2):e001076-e.
17. Boutry N, Lardé A, Lapègue F, et al. Magnetic resonance imaging appearance of the hands and feet in patients with early rheumatoid arthritis. *J Rheumatol.* 2003;30(4):671.
18. Bowen CJ, Culliford D, Allen R, et al. Forefoot pathology in rheumatoid arthritis identified with ultrasound may not localise to areas of highest pressure: cohort observations at baseline and twelve months. *J Foot Ankle Res.* 2011;4(1):25.

19. Helliwell P, Siddle H, Redmond A, editors. The foot and ankle in rheumatology. Reports on the Rheumatic Diseases; 2011.
20. Nouh MR, Khalil AA. Forefoot: a basic integrated imaging perspective for radiologists. *Clin Imaging*. 2014;38(4):397-409.
21. Sundin U, Aga A-B, Skare Ø, et al. Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis. *Rheumatology*. 2020;59(9):2550-5.
22. Matthijssen XME, Niemantsverdriet E, Le Cessie S, van der Helm-van Mil AHM. Differing time-orders of inflammation decrease between ACPA subsets in RA patients suggest differences in underlying inflammatory pathways. *Rheumatology*. 2020.
23. de Rooy DPC, van der Linden MPM, Knevel R, et al. Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic? *Rheumatology*. 2011;50(1):93-100.
24. van der Linden MPM, Batstra MR, Bakker-Jonges LE, et al. Toward a data-driven evaluation of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis: is it sensible to look at levels of rheumatoid factor? *Arthritis Rheum*. 2011;63(5):1190-9.
25. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum*. 2010;62(9):2569-81.
26. Dakkak YJ, Boer AC, Boeters DM, et al. The relation between physical joint examination and MRI-depicted inflammation of metatarsophalangeal joints in early arthritis. *Arthritis Res Ther*. 2020;22(1):67.
27. Haavardsholm EA, Østergaard M, Ejbjerg BJ, et al. Introduction of a novel magnetic resonance imaging tenosynovitis score for rheumatoid arthritis: reliability in a multireader longitudinal study. *Ann Rheum Dis*. 2007;66(9):1216-20.
28. Østergaard M, Peterfy C, Conaghan P, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. *J Rheumatol*. 2003;30(6):1385-6.
29. Nieuwenhuis WP, Mangnus L, van Steenberg HW, et al. Older age is associated with more MRI-detected inflammation in hand and foot joints. *Rheumatology*. 2016;55(12):2212-9.
30. The tendon sheaths and synovial bursae of the foot. By Gustav Schwalbe, 1896. Translated by Hartmann. *Foot Ankle*. 1981;1(5):246-69.
31. Dakkak YJ, Matthijssen XME, van der Heijde D, et al. Reliability of Magnetic Resonance Imaging (MRI) Scoring of the Metatarsophalangeal Joints of the Foot according to the Rheumatoid Arthritis MRI Score. *J Rheumatol*. 2019.
32. van der Heijde DM, van 't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. *Ann Rheum Dis*. 1990;49(11):916-20.
33. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*. 2020;79(6):685.
34. Daha NA, Toes REM. Are ACPA-positive and ACPA-negative RA the same disease? *Nat Rev Rheumatol*. 2011;7(4):202-3.

35. Matthijssen XME, Niemantsverdriet E, Huizinga TWJ, van der Helm-van Mil AHM. Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands. *PLoS Med.* 2020;17(9):e1003296.
36. Albtoush OM, Xenitidis T, Horger M. Intermetatarsal bursitis as first disease manifestation in different rheumatological disorders and related MR-imaging findings. *Rheumatol Int.* 2019;39(12):2129-36.
37. Bowen CJ, Hooper L, Culliford D, et al. Assessment of the natural history of forefoot bursae using ultrasonography in patients with rheumatoid arthritis: a twelve-month investigation. *Arthritis Care Res (Hoboken).* 2010;62(12):1756-62.
38. Endo Y, Koga T, Eguchi M, et al. Utility of power Doppler ultrasonography for detecting forefoot bursae in early rheumatoid arthritis: A case report. *Medicine (Baltimore).* 2018;97(51):e13295.
39. Heiberg T, Finset A, Uhlig T, Kvien TK. Seven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis. *Ann Rheum Dis.* 2005;64(2):191.
40. Stomp W, Krabben A, van der Heijde D, et al. Are Rheumatoid Arthritis Patients Discernible from Other Early Arthritis Patients Using 1.5T Extremity Magnetic Resonance Imaging? A Large Cross-sectional Study. *J Rheumatol.* 2014;jrheum.131169.
41. Tamai M, Kawakami A, Uetani M, et al. The presence of anti-cyclic citrullinated peptide antibody is associated with magnetic resonance imaging detection of bone marrow oedema in early stage rheumatoid arthritis. *Ann Rheum Dis.* 2006;65(1):133-4.
42. van der Woude D, van der Helm-van Mil AHM. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. *Best Pract Res Clin Rheumatol.* 2018;32(2):174-87.
43. Glinatsi D, Bird P, Gandjbakhch F, et al. Development and Validation of the OMERACT Rheumatoid Arthritis Magnetic Resonance Tenosynovitis Scoring System in a Multireader Exercise. *J Rheumatol.* 2017;44(11):1688-93.
44. Glinatsi D, Lillegraven S, Haavardsholm EA, et al. Validation of the OMERACT Magnetic Resonance Imaging Joint Space Narrowing Score for the Wrist in a Multireader Longitudinal Trial. *J Rheumatol.* 2015;42(12):2480-5.
45. van Tuyl LH, van der Heijde D, Knol DL, Boers M. Chronological reading of radiographs in rheumatoid arthritis increases efficiency and does not lead to bias. *Ann Rheum Dis.* 2014;73(2):391-5.
46. Fuhrmann RA, Layher F, Wetzel WD. Radiographic Changes in Forefoot Geometry with Weightbearing. *Foot Ankle Int.* 2003;24(4):326-31.
47. Dakkak YJ, Jansen FP, DeRuiter MC, et al. Rheumatoid Arthritis and Tenosynovitis at the Metatarsophalangeal Joints: An Anatomic and MRI Study of the Forefoot Tendon Sheaths. *Radiology.* 2020;295(1):146-54.

